To address this unmet medical need and to respond to the concerns noted in the real‐world practice, we report the development of rationally designed ADCs targeting ICAM1 as a potent targeted therapeutic for treating melanoma through direct killing of malignant cells in multiple cell line‐derived xenografts (CDX) and PDX models of melanoma. This evidence concerns the gene ICAM1 and melanoma.